organization · Reporting owner
Versant Ventures VII GP-GP, LLC
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RayzeBio, Inc.RYZB · Entity 93779 | 10% owner | September 14, 2023 | September 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RayzeBio, Inc.
Report date September 14, 2023 · Filed September 14, 2023
Jointly reported with Versant Ventures VII GP, L.P., Versant Venture Capital VII, L.P., Versant Vantage I GP-GP, LLC, Versant Vantage I GP, L.P., Versant Vantage I, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2023-09-14 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-one basis without payment of additional consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date. F3: These shares are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP-GP, LLC ("Versant VII GP LLC") is the general partner of Versant Ventures VII GP, L.P. ("Versant VII GP LP"), which is the general partner of Versant VII, and may be deemed to have shared voting, investment and dispositive power with respect to such shares. Each of Versant VII GP LLC and Versant VII GP LP disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein, if any. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2023-09-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-one basis without payment of additional consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date. F3: These shares are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP-GP, LLC ("Versant VII GP LLC") is the general partner of Versant Ventures VII GP, L.P. ("Versant VII GP LP"), which is the general partner of Versant VII, and may be deemed to have shared voting, investment and dispositive power with respect to such shares. Each of Versant VII GP LLC and Versant VII GP LP disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein, if any. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2023-09-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-one basis without payment of additional consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date. F4: These shares are held of record by Versant Vantage I, L.P. ("Vantage I"). Versant Vantage I GP-GP, LLC ("Vantage I GP LLC") is the general partner of Versant Vantage I GP, L.P. ("Vantage I GP LP"), which is the general partner of Vantage I, and may be deemed to have shared voting, investment and dispositive power with respect to such shares. Each of Vantage I GP LLC and Vantage I GP LP disclaims beneficial ownership of the shares held by Vantage I, except to the extent of their respective pecuniary interests therein, if any. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2023-09-14 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F2: Each share Series C Convertible Preferred Stock (the "Series C Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis without payment of additional consideration. Upon the closing of the IPO, the Series C Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Series C Preferred Stock has no expiration date. F4: These shares are held of record by Versant Vantage I, L.P. ("Vantage I"). Versant Vantage I GP-GP, LLC ("Vantage I GP LLC") is the general partner of Versant Vantage I GP, L.P. ("Vantage I GP LP"), which is the general partner of Vantage I, and may be deemed to have shared voting, investment and dispositive power with respect to such shares. Each of Vantage I GP LLC and Vantage I GP LP disclaims beneficial ownership of the shares held by Vantage I, except to the extent of their respective pecuniary interests therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-one basis without payment of additional consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.
F2: Each share Series C Convertible Preferred Stock (the "Series C Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis without payment of additional consideration. Upon the closing of the IPO, the Series C Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Series C Preferred Stock has no expiration date.
F3: These shares are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP-GP, LLC ("Versant VII GP LLC") is the general partner of Versant Ventures VII GP, L.P. ("Versant VII GP LP"), which is the general partner of Versant VII, and may be deemed to have shared voting, investment and dispositive power with respect to such shares. Each of Versant VII GP LLC and Versant VII GP LP disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein, if any.
F4: These shares are held of record by Versant Vantage I, L.P. ("Vantage I"). Versant Vantage I GP-GP, LLC ("Vantage I GP LLC") is the general partner of Versant Vantage I GP, L.P. ("Vantage I GP LP"), which is the general partner of Vantage I, and may be deemed to have shared voting, investment and dispositive power with respect to such shares. Each of Vantage I GP LLC and Vantage I GP LP disclaims beneficial ownership of the shares held by Vantage I, except to the extent of their respective pecuniary interests therein, if any.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LENZ Therapeutics, Inc.
Report date September 30, 2025 · Filed October 02, 2025
Jointly reported with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P.
Section 16 reporting ended · disclosed 2025-10-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,050,599 |
Last balance in matching sequence
After 2025-09-30 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-09-30 · Sale · Disposed 49,701 · Balance 1,133,842 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Row 3 · 2025-09-30 · Sale · Disposed 83,066 · Balance 1,050,776 F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Row 5 · 2025-09-30 · Sale · Disposed 177 · Balance 1,050,599 F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F2: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 821,752 |
Reported balance
After 2025-09-30 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-09-30 · Sale · Disposed 34,405 · Balance 821,752 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 764,250 |
Reported balance
After 2025-09-30 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2025-09-30 · Sale · Disposed 57,502 · Balance 764,250 F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 764,127 |
Reported balance
After 2025-09-30 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2025-09-30 · Sale · Disposed 123 · Balance 764,127 F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 842,162 |
Reported balance
Holding disclosure · report date 2025-09-30 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 842,162 F6: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
F3: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
F6: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 123 | $47.01 | $5,782.64 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 764,127 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 177 | $47.01 | $8,321.35 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,050,599 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 57,502 | $46.41 | $2,668,483.81 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 764,250 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 83,066 | $46.41 | $3,854,827.25 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,050,776 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 34,405 | $45.35 | $1,560,428.45 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 821,752 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 49,701 | $45.35 | $2,254,173.94 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,133,842 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 132 | $43.30 | $5,715.60 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 856,157 F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 268 | $43.30 | $11,604.40 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,183,543 F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 20,148 | $43.00 | $866,440.56 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 856,289 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.25 to $43.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 40,907 | $43.00 | $1,759,156.45 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,183,811 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.25 to $43.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 24,370 | $41.59 | $1,013,567.80 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 876,437 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $41.25 to $42.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 49,479 | $41.59 | $2,057,871.19 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,224,718 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $41.25 to $42.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 26, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 1,707 | $39.50 | $67,430.26 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 12 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 900,807 F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.49 to $39.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 26, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 3,465 | $39.50 | $136,875.12 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 11 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,274,197 F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.49 to $39.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 26, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 21,661 | $38.97 | $844,224.48 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 10 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 902,514 F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.50 to $39.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 26, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 43,978 | $38.97 | $1,714,016.16 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 9 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,277,662 F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.50 to $39.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 1,058 | $39.92 | $42,236.63 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 8 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 924,175 F6 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.81 to $40.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 2,149 | $39.92 | $85,790.66 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 7 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,321,640 F6 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.81 to $40.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 24,760 | $39.53 | $978,651.38 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 925,233 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.815 to $39.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 50,270 | $39.53 | $1,986,946.89 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,323,789 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.815 to $39.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 2,809 | $40.59 | $114,017.03 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 949,993 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $40.50 to $40.8819, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 5,668 | $40.59 | $230,063.55 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,374,059 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $40.50 to $40.8819, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 10,076 | $40.03 | $403,339.26 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 952,802 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.5085 to $40.4616, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 20,493 | $40.03 | $820,328.64 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,379,727 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.5085 to $40.4616, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 20:51 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 15,085 | $38.56 | $581,694.19 |
DisclosureSEC source: 0000950170-25-110163 · ownership.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 962,878 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.26 to $39.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 20:51 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 30,628 | $38.56 | $1,181,049.37 |
DisclosureSEC source: 0000950170-25-110163 · ownership.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,400,220 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.26 to $39.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:51 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 69,949 | $39.50 | $2,762,985.50 |
DisclosureSEC source: 0000950170-25-110163 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 977,963 F2 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:51 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 145,051 | $39.50 | $5,729,514.50 |
DisclosureSEC source: 0000950170-25-110163 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,430,848 F1 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 10, 2025 Filed Jul 14, 2025 20:50 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 191,376 | $34.00 | $6,506,784.00 |
DisclosureSEC source: 0000950170-25-095616 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,575,899 F1 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 22:16 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 200,000 | $30.47 | $6,093,000.00 |
DisclosureSEC source: 0000950170-25-092373 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,767,275 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $30.18 to $30.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 21:50 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 133,924 | $30.25 | $4,051,201.00 |
DisclosureSEC source: 0000950170-25-088604 · ownership.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,967,275 F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 21:50 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 100,877 | $30.35 | $3,061,616.95 |
DisclosureSEC source: 0000950170-25-088604 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,047,912 F1 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 21:50 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 100,000 | $29.95 | $2,995,000.00 |
DisclosureSEC source: 0000950170-25-088604 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,148,789 F1 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:37 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 350,000 | $29.00 | $10,150,000.00 |
DisclosureSEC source: 0000950170-25-085490 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,248,789 F1 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:30 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | OtherCommon Stock | 598,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-035951 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 842,162 F1 · kind: These shares were acquired pursuant to that certain Agreement and Plan of Merger by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), and Lenz Therapeutics, Inc., a Delaware corporation ("LENZ"), pursuant to which the Merger Sub merged with and into LENZ (the "Merger"), with LENZ continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the Merger. F1 · price: These shares were acquired pursuant to that certain Agreement and Plan of Merger by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), and Lenz Therapeutics, Inc., a Delaware corporation ("LENZ"), pursuant to which the Merger Sub merged with and into LENZ (the "Merger"), with LENZ continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the Merger. F2 · balance_after: Effective March 21, 2024, prior to the closing of the Merger, the Issuer effected a one-for-seven reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F3 · ownership.nature: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP disclaims beneficial ownership of the shares held by VV II, except to the extent of their respective pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.